{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:59:48Z","timestamp":1774529988757,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:00:00Z","timestamp":1534550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10157-018-1630-y","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T07:47:03Z","timestamp":1534578423000},"page":"207-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study"],"prefix":"10.1007","volume":"23","author":[{"given":"Takayuki","family":"Katsuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"key":"1630_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0272-6386(12)80353-2","volume":"17","author":"S Fujimoto","year":"1991","unstructured":"Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis. 1991;17:687\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1630_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","volume":"39","author":"M Nakayama","year":"2002","unstructured":"Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002;39:503\u201312.","journal-title":"Am J Kidney Dis"},{"key":"1630_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s10157-016-1371-8","volume":"21","author":"M Sato","year":"2017","unstructured":"Sato M, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term outcomes of initial therapy for idiopathic membranous nephropathy. Clin Exp Nephrol. 2017;21:842\u201351.","journal-title":"Clin Exp Nephrol"},{"key":"1630_CR4","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23:1416\u201325.","journal-title":"J Am Soc Nephrol"},{"key":"1630_CR5","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2169\/internalmedicine.56.7908","volume":"56","author":"T Katsuno","year":"2017","unstructured":"Katsuno T, Ozaki T, Kim H, Kato N, Suzuki Y, Akiyama S, et al. Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: a single-center experience. Intern Med. 2017;56:1679\u201386.","journal-title":"Intern Med"},{"key":"1630_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21:193\u2013202.","journal-title":"Clin Exp Nephrol"},{"key":"1630_CR7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794\u20137.","journal-title":"Pediatr Nephrol"},{"key":"1630_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"1630_CR9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1630_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, Gu\u00e9rin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1630_CR13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26:2259\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"1630_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"1630_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511\u20136.","journal-title":"Kidney Int"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"1630_CR17","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1097\/MD.0000000000000300","volume":"93","author":"Y Iwabuchi","year":"2014","unstructured":"Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltim). 2014;93:e300.","journal-title":"Medicine (Baltim)"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","volume":"29","author":"J Guitard","year":"2014","unstructured":"Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014;29:2084\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"1630_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ndt\/gft312","volume":"29","author":"A Bruchfeld","year":"2014","unstructured":"Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant. 2014;29:851\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"1630_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28:1225\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"1630_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10157-015-1216-x","volume":"20","author":"S Nishi","year":"2016","unstructured":"Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20:342\u201370.","journal-title":"Clin Exp Nephrol"},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1630_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1042\/CS20040095","volume":"107","author":"JG Berg van den","year":"2004","unstructured":"van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond). 2004;107:125\u201336.","journal-title":"Clin Sci (Lond)"},{"key":"1630_CR24","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46.","journal-title":"Sci Transl Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1630-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T17:23:14Z","timestamp":1567099394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1630-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1630-y","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The Department of Nephrology and Rheumatology, Aichi Medical University received research promotion grants from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Limited., and Torii Pharmaceutical Co., Ltd. The Department of Nephrology, Nagoya University Graduate School of Medicine received research promotion grants from Astellas Pharma Inc., Bristol-Myers Squibb., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Limited., Torii Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of The Ethics Committee for Human Research of Nagoya University Hospital at which the studies were conducted (IRB approval number 2017-0192) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The Ethical Committee approved this retrospective cohort study without written informed consent from patients; however, informed consent was obtained from most patients at the time of performing a renal biopsy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}